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Abstract
Objective: to assess the prevalence of and factors associated with the use of benzodiazepines 
in elderly persons living in the community. Method: a cross-sectional study was conducted 
through a household survey of 423 elderly persons from Juiz de Fora, Minas Gerais, 
Brazil. To analyze the factors associated with the outcome, the Poisson regression model 
was used, based on the theoretical model of determination with hierarchical blocks. 
The variables were adjusted within each block, with those with a 5% significance level 
remaining in the final model. Result: The prevalence of benzodiazepine use was 18.3% 
(95% CI 15.2 to 21.6). Most benzodiazepines used had a long-elimination half-life (59.2%) 
and use was considered long in 85.5% of users. Among benzodiazepine users 38.4% also 
used antidepressants. The use of these drugs was associated with the presence of self-
reported mental and behavioral disorders, polypharmacy and medical visits in the last 
three months. Conclusion: The use of benzodiazepines was considered high among the 
elderly. The reduction in the prescription of these drugs should be assessed individually, 
considering the physiological alterations of the elderly and the adverse effects of drugs, 
in order to minimize incorrect prescriptions.
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INTRODUC TION
Greater susceptibility to chronic diseases, 
disabilities, psychosocial problems and comorbidities 
are more prevalent in old age. The process of 
population has brought about a growing concern 
about mental health care, mainly due to the high 
prevalence of mental disorders in the elderly 
population, particularly mood and anxiety disorders1. 
The use of medication is one of the main forms 
of treatment for the control and prevention of the 
most prevalent chronic health conditions, especially 
in the case of the elderly. The elevated use of drugs 
makes this population more susceptible to the 
risks of polypharmacy and problems related to 
pharmacotherapy2.
Among the medications used by the elderly, 
the chronic use of psychotropic drugs, especially 
benzodiazepine class hypnotics, sedatives and 
anxiolytics, is highlighted, due to the constant 
insomnia and anxiety that affect this group. Chronic 
use of psychoactive drugs can lead to serious 
consequences, such as increased drug interactions, 
adverse reactions, and the development of dependence 
and tolerance. The elevated consumption of drugs, 
especially of psychoactive drugs, may be related to 
the reduction of functional capacity and consequently 
a low quality of life3.
The evelated use of psychotropic drugs emphasizes 
the need for intervention4. Benzodiazepines are 
highly prominent among psychotropic drugs, and 
their popularization has revealed new problems, 
mainly due to inadequate use. Chemical dependence 
on benzodiazepines with all the inherent implications 
of such conditions has become a major concern for 
public health.
The prolonged use of benzodiazepines is 
associated with many adverse effects, including 
sedation, amnesia, cognitive impairment and ataxia, in 
addition to a greater number of falls5. Such drugs also 
add to the development of psychological dependence 
in chronic benzodiazepine users, and both physicians 
and patients have difficulty implementing protocols 
to reduce their use. Many patients deny or minimize 
side effects, or express a reluctance to risk suffering 
without the drug6.
It is essential to understand the patterns of 
medication use by the elderly population, in order 
to establish ways to ensure their rational use, the 
improvement in quality of life and the maintenance of 
functional capacity. Given the above, the present study 
aims to evaluate the prevalence of benzodiazepine 
use in the elderly and associated factors.
 
METHOD
The present study originates from an observational 
follow-up study of elderly residents in the northern 
zone of the city of Juiz de Fora, Minas Gerais, Brazil. 
The present study is part of the second cross-sectional 
phase. The northern zone is the region of the city 
with the greatest territorial availability in the urban 
area and has the second largest population in the 
municipality, as well as having the largest number 
of neighborhoods, concentration of unplanned 
communities and social programs7.
Data were obtained through two household 
surveys conducted in 2010 and 2014-2015. The 
individuals were selected by conglomerate sampling, 
and the primary sampling subunits were the census 
tracts. As the current survey has multiple outcomes, 
the sample size was calculated based on a prevalence 
of 50%, deff 1.5 (considering stratification effect and 
cluster) and a significance level of 95%.
All the elderly participants of the first survey 
(2010) were visited again. Losses over time included a 
change of address where it was not possible to obtain 
the new address, where the elderly person was not 
found after three attempts at contact at different 
times and on different days, and refusals. The losses 
were not differential. To compensate for losses, the 
oversample8 method was used, considering cluster 
sampling. Thus, 248 elderly people included in the 
2010 sample participated in the present study, in 
addition to 175 new elderly people, and the study 
was composed of 423 individuals.
The questionnaire used was standardized and 
previously tested. Data collection was performed 
at the homes of the elderly persons between 
September 2014 and March 2015. Quality control 
of the information collected was performed, in which 
10% of the sample was evaluated by a new partial 
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interview. The Mini Mental State Exam (MMSE) 
was used to screen for cognitive impairment9. Elderly 
persons who did not reach the minimum established 
for the study10 had their questionnaires answered 
by a caregiver/family member. In such cases, self-
perception questions were not answered. In the 
absence of another respondent, the elderly were 
excluded from the study.
The dependent variable was the continuous use 
of benzodiazepines. The independent variables were 
selected based on theoretical reference11-14 and were 
grouped into three blocks. The first block included 
the sociodemographic variables (distal determinants), 
which are responsible for conditioning the variables 
of the other blocks. The second block (intermediate 
determinants) included variables related to the health 
of the elderly. Variables relating to health services 
were allocated in the third block.
The variables of each block included: Block 1) 
sociodemographic variables: gender; age; schooling; 
ethnicity (white, black, yellow (Asian-Brazilian), 
brown (mixed-race), indigenous); marital status 
(single, married/stable, widowed, separated/divorced, 
other); home arrangement (lived alone or with 
others); Block 2) variables related to the health of 
the elderly: perception of health, vision and hearing 
(excellent, very good, good, fair and poor); self-
reported comorbidities (classified according to the 
International Classification of Diseases - ICD 10), 
including diseases of the nervous system, mental and 
behavioral disorders; frailty measured according to the 
Edmonton scale15 (does not present frailty, apparently 
vulnerable, mild frailty, moderate frailty and severe 
frailty); functional capacity for the performance 
of instrumental activities of daily living (IADL) 
classified by the Lawton-Brody scale16 (dependence, 
partial dependence and independence); suggestion of 
anxiety and/or depression, according to the Patient 
Health Questionnaire (PHQ-4) scale17; falls in the 
last year (yes or no); continuous-use medication (yes 
or no); polypharmacy18 (yes or no); Block 3) variables 
related to the health service: type of coverage of the 
public health service [discovery area, Basic Health 
Unit (BHU) with Family Health Strategy, traditional 
BHU]; possesses a health plan (yes or no); satisfaction 
with medical health service (yes or no), including 
public and private services; medical consultation in 
the last three months (yes or no).
In order to evaluate the use of medicines, the 
question used was: "Do you continuously use any 
medication?" If so, the boxes or blister packs of 
the medication were analyzed. In the absence of 
these, the information was completed according 
to the reports of the elderly. The study considered 
polypharmacy to be the use of five or more drugs18. 
Benzodiazepines were classified according to their 
elimination half-life19: short/intermediate acting 
(half-life up to 24 hours) and long-acting (half-life 
greater than 24 hours). The time of continuous 
treatment with benzodiazepines was stratified as 
up to six months of treatment or greater than six 
months, the second case being considered as a 
prolonged period20.
Initially the data were submitted to descriptive 
univariate analysis to obtain the absolute and 
relative frequency of the variables analyzed, as 
well as the prevalence of the investigated variable. 
For the quantitative variables, measures of central 
tendency and dispersion were calculated. The chi-
square test was used in the bivariate analysis to verify 
the association between each of the independent 
variables and the dependent variable. 
Multivariate analysis was based on the proposed 
theoretical model of determination with hierarchical 
blocks of variables (Figure 1) to control for possible 
confounding factors. Initial adjustment was 
performed within each block, with variables with 
a level of significance less than or equal to 0.20 in 
the bivariate analysis included. The variables that 
achieved a score of p<0.05 in the block analysis 
were maintained in the final model, with those 
that retained a significance level of 5% ( p <0.05), 
controlled by all the significant variables of the blocks 
immediately above, included in this model. For the 
multivariate analysis, the Poisson regression model 
was used to estimate crude and adjusted prevalence 
ratios, with a robust estimate of variance and a 95% 
confidence interval (95%CI).
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The study was approved by the Ethics Research 
Committee of the Universidade Federal de Juiz de 
Fora (Juiz de Fora Federal University), under approval 
n. 771.916, and a Free and Informed Consent Form 
was signed by all the participants.
RESULTS
A total of 423 questionnaires were analyzed, 
of which 23 were excluded due to poor MMSE 
performance and the lack of another respondent. 
The final sample consisted of 400 elderly individuals, 
with 315 (78.8%) questionnaires answered by the 
elderly themselves and 85 (21.2%) by another 
respondent. 
The majority of the participants were women 
(64.5%), lived with another person (89.5%), were 
married or in a common-law marriage (55.8%), and 
declared themselves as white (45.5%). The mean age 
was 73.8 years (±8.0) and mean schooling was 4.2 
years (±3.4).
A poor or fair health perception was reported by 
43.5% of the elderly, 54.9% described having fair or 
poor vision, and 28.6% had fair or poor hearing. The 
presence of comorbidities was reported by 89.0% of 
the elderly persons, and 4.8% reported diseases of 
the nervous system and 11.3% mental and behavioral 
disorders. Most were independent in the assessment 
of functional capacity for instrumental activities of 
daily living (Lawton and Brody Scale, 84.5%) and 
presented some level of frailty (Edmonton Scale, 
57.8%). A suggestion of anxiety was verified in 
72.7% of the elderly and there was a suggestion of 
depression in 77.1% (PHQ-4 Scale).
In terms of health services, the majority of the 
elderly resided in an area that had BHU care within 
the Family Health Strategy (74.0%) and 60.3% had a 
health plan. Of the elderly who used medical health 
services, 81.3% were satisfied with the service. The 
prevalence of a medical consultation in the last three 
months was 76.0%. The characteristics of the sample 
according to the independent variables are described 
in Table 01.
Figure 1. Theoretical model of investigation of the effects of the independent variables on the use of benzodiazepine 
in hierarchical blocks. Juiz de Fora, MG, 2015.
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Table 1. Characteristics of the sample according to the use of benzodiazepines. Juiz de Fora, Minas Gerais, 2015.
Variables 
Use of benzodiazepines
Yes. n (%) No. n (%)
Sociodemographic variable
Gender
Male 19 (26.0) 123 (37.6)
Female 54 (74.0) 204 (62.4)
Age (years)
60 - 69 25 (34.2) 111 (33.9)
70 - 79 33 (45.2) 132 (40.4)
80 or more 15 (20.5) 84 (25.7)
Variables related to the health of the elderly person
Comorbidities
Presence 68 (93.2) 288 (88.1)
Absence 5 (6.8) 39 (11.9)
Nervous system diseases*
Yes 8 (11.8) 9 (3.1)
No 60 (88.2) 278 (96.9)
Mental and behavioral disorders*
Yes 18 (26.5) 22 (7.7)
No 50 (73.5) 265 (92.3)
Functional Capacity for the performance of IADL
Independent 62 (84.9) 276 (84.4)
Partial Dependency to Dependency 11 (15.1) 51 (15.5)
Suggestion of Anxiety*
No 34 (58.6) 195 (75.9)
Yes 24 (41.4) 62 (24.1)
Suggestion of Depression*
No 39 (67.2) 204 (79.4)
Yes 19 (32.8) 53 (20.6)
Frailty*
Did not exhibit frailty 16 (27.6) 127 (45.2)
Apparently vulnerable 10 (17.2) 65 (23.1)
Mild frailty 13 (22.4) 51 (18.1)
Moderate to severe frailty 19 (32.7) 38 (13.5)
Falls in last year
Yes 27 (37.0) 114 (34.9)
No 46 (63.0) 213 (65.1)
Polypharmacy*
Yes 51 (69.9) 127 (43.1)
No 22 (30.1) 168 (56.9)
Variables related to health service
Satisified with health service*
Yes 63 (86.3) 258 (80.1)
No 10 (13.7) 64 (19.9)
Medical consultation in last three months
Yes 66 (90.4) 238 (72.8)
No 7 (9.6) 89 (27.2)
IADL: instrumental activities of daily living; *Excluding non-respondents.
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In terms of pharmacological therapy, 92.0% of 
the elderly used at least one continuous-use drug. Of 
these, 48.4% used five or more drugs, characterized 
as polypharmacy. The average number of medications 
used by the elderly was 4.8 (±2.9).
The prevalence of benzodiazepine use in the 
population was 18.3% (95% CI 15.2-21.6) (73/400), 
with clonazepam, bromazepam and alprazolam 
being the most commonly used benzodiazepines. 
In addition, 4.1% (3/73) of the elderly used two 
benzodiazepines. Most of the benzodiazepines 
used by the elderly in the present study had a long 
elimination half-life (half-life greater than 24 
hours, 59.2%). The time of benzodiazepine use 
was greater than six months in 85.5% of users. 
Among the benzodiazepine users, 38.4% also used 
antidepressants. The characterization of the use of 
benzodiazepines by the elderly is described in Table 2.
The variables that remained associated with the 
use of benzodiazepines in the bivariate analysis 
and the adjusted prevalence ratios within each 
hierarchical block are described in Table 3. In block-
adjusted multivariate analysis, no block 1 variable 
was statistically significant (p<0.05). In block 2, the 
variables auditory perception, self-report of mental 
and behavioral disorders and polypharmacy were 
significant. The only significant variable in block 3 
was medical consultation in the last three months.
After multiple regression analysis, three variables 
associated with the use of benzodiazepines remained 
in the final model (Table 4): presence of self-reported 
mental and behavioral disorders (adjusted PR =4.72, 
95%CI, 1.88-11.82), polypharmacy (adjusted PR 
=2.17, 95%CI, 1.14-4.35) and medical consultation 
in the last three months (adjusted PR =6.64, 95%CI 
1.51-29.22).
















Time of use (months)*
Up to 6 9/62 (14.5)
Over 6 53/62 (85.5)
*Variable investigated only when respondent was the elderly person themselves.
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Table 3. Use of benzodiazepines according to independent variables. Juiz de Fora, Minas Gerais, 2015.
Variables % Crude PR(CI 95%) p
Adjusted PR
(CI 95%) p
Block 1 – Sociodemographic variables
Gender 0.061 0.093
Female 20.9 1 1
Male 13.4 0.58 (0.33-1.03) 0.61 (0.34-1.08)
Schooling (years) 0.141 0.221
5 or more 14.6 1 1
1 to 4 18.5 1.34 (0.71-2.52) 1.33 (0.87-2.02)
0 24.5 1.90 (0.81-4.45) 1.33 (0.87-2.02)
Block 2 – Variables related to the health of the elderly person
Perception of Health* 0.023 0.098
Fair/Poor 24.1 1 1
Excellent to Good 14.0 0.51 (0.29-0.92) 0.48 (0.20-1.15)
Perception of Hearing* 0.039 0.048
Fair 25.6 1 1
Excellent to Good 15.6 0.54 (0.30-0.97) 0.45 (0.20-0.99)
Nervous system diseases* 0.003 0.074
No 17.8 1 1
Yes 47.1 4.12(1.53-11.11) 4.68 (0.86-25.40)
Mental and behavioral disorders* <0.001 0.007
No 15.9 1 1
Yes 45.0 4.34 (2.17-8.67) 5.38 (1.57-18.44)
Suggestion of Anxiety* 0.008 0.750
Yes 27.9 1 1
No 14.8 0.45 (0.25-0.82) 0.87 (0.37-2.06)
Suggestion of Depression* 0.047 0.565
Yes 26.4 1 1
No 16.0 0.53 (0.28-1.0) 0.76 (0.29-1.95)
Frailty* 0.009 0.118
Present 21.4 1 1
Absent 11.2 0.46 (0.25-0.86) 2.23 (0.82-6.08)
Polypharmacy* <0.001 0.023
No 11.6 1 1
Yes 28.7 3.03 (1.79-5.26) 2.56 (1.14-5.88)
Use of antidepressants <0.001 0.086
No 13.4 1 1
Yes 44.4 5.19 (2.88-9.34) 2.42 (0.88-6.63)
Block 3 – Variables related to health service
Health Plan 0.111 0.116
No 14.5 1 1
Yes 20.7 1.55 (0.90-2.66) 1.55 (0.90-2.68)
Medical consultation in last three months <0.001 0.002
No 7.3 1 1
Yes 21.7 3.53 (1.56-7.97) 3.53 (1.56-8.00)
*Excluding non-respondents.
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DISCUSSION
The prevalence of benzodiazepine use in the study 
population was 18.3%, similar to that found in other 
studies11,12. Prevalences that differ from the present 
study have also been reported in literature13,14,21. 
Differences between studies can be explained by 
the difference in definitions of use and the period 
of observation. The present study analyzed drugs in 
continuous use at the time of the interview, while 
others evaluated medication use in the 15 days, 90 days 
or 12 months prior to the interview. The contrasts 
identified may also reveal important differences 
among the analyzed populations, such as health 
service use, epidemiological profile, sociocultural 
characteristics, or even reflect the habits of those 
prescribing the drugs, in addition to the criteria used 
to indicate these medications14. 
The high consumption of benzodiazepines may 
be related to the progressive decrease in humanity's 
resistance to stress, the introduction of new drugs, 
the increasing pressure of advertising by the 
pharmaceutical industry, or inadequate prescription 
habits on the part of professionals22. It should also 
be added that drugs are considered one of the main 
contemporary technologies of care, and promise to 
ward off any suffering caused by society, such as 
depression, anxiety, psychotic disorders, loneliness, 
economic crises and sadness, simply through the 
administration of an effective chemical in the body4.
The long-term use of benzodiazepines in 85.5% 
of the elderly and the high prevalence of long 
half-life benzodiazepines (59.2%) are noteworthy. 
Long-acting benzodiazepines accumulate when 
taken repeatedly and their undesirable effects may 
manifest themselves after several days or weeks23. 
According to the Beers-Fick and STOPP criteria 
for drugs that are inappropriate for the elderly, the 
use of benzodiazepines should be avoided in such 
individuals, regardless of the half-life of the drug24,25. 
Restrictions on the use of benzodiazepines by the 
elderly have been increasing, related to depression 
of the central nervous system, such as decreased 
psychomotor activity, memory impairment and 
the potentiation of the depressive effect through 
interaction with other depressant drugs22. Literature 
indicates that even short-acting benzodiazepines are 
a significant risk factor for the frequency of falls in 
geriatric patients26.
A prospective study by Billioti de Gage et al.27 
showed that the use of benzodiazepines is associated 
with an increased risk of dementia. The risk of 
dementia increases with cumulative dose, duration 
of treatment, and when long-acting drugs are used27. 
Specific concerns about prolonged use also include 
the development of tolerance and increased dosage, 
addiction, drug abuse and difficulty of withdrawal5,6. 
Drug dependence leads to the annulment of responses 
to social suffering related to gender, aging and poor 
Table 4. Final regression model of association of benzodiazepine use and independent variables. Juiz de Fora, 
Minas Gerais, 2015.
Variables Crude PR(CI 95%) p
Adjusted PR
(CI 95%) p
Mental and behavioral disorders* 0.007 0.001
No 1 1
Yes 5.38 (1.57-18.44) 4.72 (1.88-11.82)
Polypharmacy* 0.023 0.020
No 1 1
Yes 2.56 (1.14-5.88) 2.17 (1.14-4.35)
Medical consultation in last three months 0.002 0.012
No 1 1
Yes 3.53 (1.56-8.00) 6.64 (1.51-29.22)
*Excluding non-respondents.
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economic and quality of life conditions, promoting 
psychiatric illnesses such as anxiety and depression, 
which can be intensified in the elderly and stimulated 
by the continuous use of medications28. 
The difficulty of withdrawing benzodiazepine 
use from patients who have become dependent 
due to prolonged use is also an important issue. 
Modifying consumption in patients who have 
used benzodiazepines for several years remains 
a challenge. The reason for the continued use of 
benzodiazepines is described as a fear of the return 
and intensification of symptoms, or impairment of 
the performance of daily activities. Psychological 
dependence and the underestimation or negation 
of the potential side effects of benzodiazepines 
contribute to the resistance, especially of the elderly, 
to discontinuing medication29.
Factors associated with the use of benzodiazepines 
found in the present study following multivariate 
analysis were the presence of mental and behavioral 
disorders, polypharmacy and a medical consultation 
in the last three months. An association between the 
use of benzodiazepines and mental and behavioral 
disorders was verified in other studies, with use 
associated with common mental disorders11 and 
previous psychiatric illnesses20. 
The associat ion bet ween the use of 
benzodiazepines and the use of other drugs has been 
verified in literature11. In the present study the use of 
benzodiazepines was associated with polypharmacy. 
The presence of comorbidities and consultation with 
different specialists may be related to this practice14. 
Polypharmacy does not necessarily indicate that the 
prescription and use of the drugs is incorrect, and 
it is often necessary to guarantee a better quality of 
life for the elderly person30. However, the number 
of drugs prescribed, the complexity of therapeutic 
regimens, especially in the case of comorbidities, 
and the pharmacokinetic and pharmacodynamic 
changes inherent in the aging process, increase the 
vulnerability of the elderly to medications, whether 
due to adverse reactions, drug interactions or side 
effects31. In a study by Richardson et al.5, it was 
found that the use of benzodiazepines was associated 
with an increased risk of falls when combined with 
polypharmacy.
The periodic medical consultations by users of 
benzodiazepines may be justified by the fact that 
these drugs are only dispensed with a medical 
prescription, and the amount dispensed is only 
sufficient for a maximum of 60 days of treatment. 
Studies have confirmed this association11,12. Contact 
with the medical service is seen as an opportunity 
to obtain the prescription of a psychotropic drug12. 
On the other hand, the use of benzodiazepines may 
increase the patient's contact with the physician. 
According to Auchewski et al.22, a return visit to 
the doctor may be interpreted as the desire of the 
prescriber to accompany the response of the patient 
to the benzodiazepines, including dose monitoring, 
evaluation of side effects and therapeutic response. 
A return visit to the doctor should be seen as a 
precaution, as a rational prescription should be 
based on the continuous monitoring of the patient. 
However, in practice, it has been observed that 
patients only return to obtain a new prescription. 
A study carried out by Alvarenga et al.32 reports 
the ease of the acquisition of prescriptions, which 
can be obtained without the need for a formal 
medical consultation or adequate medical guidance 
on the care needed during treatment. A link is not 
established with the medical professional or with the 
health service, but with the medication itself, with 
the need to present a prescription being understood 
as an obstacle. 
The use of benzodiazepines in geriatrics should 
be carried out with discretion and according to 
specific criteria, since the sensitivity of the elderly 
to benzodiazepines and their half-life increases 
considerably with age. Despite the growing 
concern, the use of benzodiazepines by the elderly 
remains high. This is largely because no superior 
pharmacotherapeutic alternative has been developed 
to treat anxiety and insomnia. Benzodiazepines act 
fast and, at least in the initial prescription stage, are 
safe and possess predictable effects33. 
Reducing the prescription of benzodiazepines 
requires replacement with other treatments for 
sleep disorders and anxiety, many of which are 
non-pharmacological12. Gradual cessation of use 
may be effective, with a gradual reduction in dose. 
Cognitive behavioral therapy is considered effective 
for the treatment of chronic insomnia, facilitating 
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the reduction of the use of benzodiazepines in the 
elderly34. Interventions in the areas of prescription, 
substitution, psychotherapies and pharmacotherapies 
may contribute to the management of benzodiazepine 
dependence. Efforts should be made to educate and 
support patients. In addition, proper interaction 
between medical professionals and patients may 
contribute to tackling the problem of inappropriate 
prescriptions.
Consideration should be given to the limitations 
of the present study, mainly due to its cross-sectional 
design, which does not allow the evaluation of 
temporal relationships, as well as the impossibility 
of identifying the therapeutic indication of the drug, 
the existence of adverse events and the occurrence 
of drug interactions. The advantages of the study 
should also be highlighted, such as the fact that 
it was performed with elderly people living in the 
community, and so is less prone to selection bias 
than studies conducted in selected populations11.
CONCLUSION
The prevalence of the chronic use of 
benzodiazepines in the elderly was considered 
high, and similar to findings in literature. The use 
of benzodiazepines was associated with mental and 
behavioral disorders, polypharmacy and medical 
consultations. Prescription in the elderly, as well as 
prolonged use, should be evaluated with caution, 
considering the physiological changes among this 
population and the adverse effects of the medications.
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